Aberdeen Group’s AgomAb Therapeutics NV AGMB Stock Holding History
Bought
Maintained
Sold
Other funds holding AGMB
SL
Aberdeen Group's AGMB Position: Q3 2026 in Review
Aberdeen Group increased its AgomAb Therapeutics NV (AGMB) stake by 46% in Q3 2026, buying an estimated $5.05M and bringing the position to 1,237,401 shares worth $13.7M. The position accounts for 0.02% of the portfolio, ranked #531.
Aberdeen Group first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.
- Aberdeen Group held 1,237,401 shares of AgomAb Therapeutics NV worth $13.7M as of Q3 2026.
- Aberdeen Group bought 390,706 AgomAb Therapeutics NV shares in Q3 2026, an estimated $5.05M.
- AgomAb Therapeutics NV made up 0.02% of Aberdeen Group's portfolio in Q3 2026, its #531 holding.
- Aberdeen Group first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
- 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.
Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.